Neoadjuvant intra-arterial chemotherapy in patients with primary lacrimal adenoid cystic carcinoma
© Jang et al.; licensee BioMed Central Ltd. 2014
Received: 6 March 2014
Accepted: 6 March 2014
Published: 29 April 2014
We describe four cases of primary lacrimal adenoid cystic carcinoma (ACC) treated with neoadjuvant intra-arterial chemotherapy (NAIC).
The outcomes and complications of NAIC were reviewed. Several treatment-related local and/or systemic complications were noted.
One patient experienced ipsilateral eyelid and eyeball necrosis and permanent facial palsy; the second patient developed ipsilateral facial swelling and jaw claudication; and the third patient had febrile neutropenia, cellulitis, and phlebitis. These three patients underwent total exenteration. The fourth patient experienced neutropenia and thrombocytopenia and underwent tumour removal without exenteration. All patients were followed for more than 4 years and were alive at the last follow-up.
Neoadjuvant intra-arterial chemotherapy may be an alternative treatment that will improve the survival rate of ACC. However, careful and close observation is needed to minimise the risk of side effects. Further investigations are needed to justify the use of chemotherapy-related treatments and the associated costs.
KeywordsAdenoid cystic carcinoma Neoadjuvant intra-arterial chemotherapy Complication
Primary lacrimal adenoid cystic carcinoma (ACC) is a rare, aggressive, malignant epithelial cancer with reported survival rates of less than 50% at 5 years and 20% at 10 years [1, 2]. In our institution, the Severance Hospital, we usually perform total exenteration, neighbouring bone resection, adjuvant radiation therapy, and systemic chemotherapy in patients with ACC. Such aggressive treatments should be considered due to the poor prognosis of ACC [1, 2]. Advances in imaging technology have enabled the detection of this cancer at an early stage. Moreover, supplementary treatments, such as radiation therapy and chemotherapy, also play an important role in enhancing survival rates by preventing recurrence and metastasis. In 1998, Meldrum et al.  first introduced the concept of neoadjuvant chemotherapy in the ophthalmological field through the treatment of two patients with advanced ACC of the lacrimal gland. The two patients had survived for 7.5 and 9.5 years at the last follow-up, thereby establishing the use of neoadjuvant chemotherapy in the treatment of ACC as a new paradigm. In 2006, Tse et al.  reported nine patients in whom neoadjuvant chemotherapy was used to treat ACC successfully, emphasising the usefulness of this treatment for local disease control and the enhancement of disease-free survival.
We performed neoadjuvant intra-arterial chemotherapy (NAIC) using the modified methods of Meldrum et al.  and Tse et al.  for four patients who visited our institution between February 2007 and May 2009. The aim of the present study was to report the complications related to NAIC. In addition, we also discuss an interventional method in terms of selecting an artery for NAIC that has not been reported previously in the literature.
This study was a non-comparative, consecutive case series. We conducted chart reviews of four survivors who visited the Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, between February 2007 and May 2009. All patients were diagnosed with primary lacrimal ACC and underwent NAIC. The patients had no intracranial infiltration or distant metastasis at the initial presentation. The tumour stage in all patients was T4N0M0 according to the staging criteria of the American Joint Committee on Cancer . All patients were subjected to incisional biopsy to confirm the histological diagnosis. All patients agreed to the NAIC following full discussion of the poor prognosis of the disease, current treatment strategy, complications related to NAIC, and the uncertainty regarding the effectiveness of the treatment.
Demographics, clinical presentations, radiological imaging, and histopathological data were investigated. We reviewed the radiological images during the NAIC, the local and systemic complications after treatment, and the presence of local recurrence and distal metastasis. The status at the last follow-up was also evaluated. Approval to conduct this retrospective study was obtained from the Institutional Review Board of Severance Hospital of Yonsei University.
Neoadjuvant intra-arterial chemotherapy technique
Bilateral internal and external carotid angiography was performed through a transfemoral approach with adequate precautions, using a 4 F or 5 F Headhunter diagnostic catheter (COOK MEDICAL INC., Bloomington, IN, USA). The primary feeding artery that stains the lacrimal gland (usually a branch of the lacrimal artery) was identified. The lacrimal artery can branch out from the ophthalmic artery (a branch of the internal carotid artery (ICA)) or from the middle meningeal artery (a branch of the external carotid artery (ECA)) as the meningo-lacrimal variant [6–8]. After defining the arterial anatomy, the diagnostic catheter was replaced for a 5 F Envoy® Guiding Catheter (Cordis Corporation, Miami Lakes, FL, USA). Subsequently, a Prowler® 14 microcatheter (Cordis Corporation) was coaxially introduced through the guiding catheter to attempt superselective cannulation of the artery feeding the lacrimal gland. The chemotherapeutic agent was infused through the microcatheter. During the chemoinfusion, intermittent fluoroscopic monitoring was done to ascertain adequate catheter position. We administered up to 3000 units of heparin intravenously during the procedure to prevent catheter-related thrombotic complications. Post-infusion angiography was performed to exclude any complications.
In our practice, NAIC needs 3 days of hospitalisation. On the first day of admission, intra-arterial chemoinfusion of cisplatin is done using the aforementioned technique; 60–80 mg/ m2 of cisplatin is diluted in 500 ml of normal saline solution and injected over 1 hour. Doxorubicin (20–25 mg/m2) is given intravenously for 3 days from the first day of hospitalisation. Thus, each chemotherapy cycle lasts 3 days, and the interval between two cycles is 21 days. A total of three cycles is regarded as completion of the regimen. Patients are followed up with computed tomography (CT) scans to assess the response. Orbital exenteration is done 3–4 weeks after the last NAIC cycle. Surgery is followed by radiation therapy (RT; dose, 6000 cGy) administered using a standard daily fraction protocol.
Clinical summary of patients with lacrimal adenoid carcinoma treated with neoadjuvant intra-arterial chemotherapy
Ipsilateral eyelid and eyeball necrosis, permanent facial palsy
Tubular pattern ACC
Facial swelling and tenderness, difficulties in chewing
Febrile neutropenia, cellulitis
Tumour resection only
A 35-year-old pregnant woman presented with a 3-month history of progressive right proptosis. Exophthalmometry showed a 2-mm proptosis in the right eye. She was pregnant and hence denied any further investigations. At a later follow-up, 1 month from childbirth, a right-sided proptosis of approximately 4 mm was identified and it was accompanied by ocular pain and conjunctival hyperaemia. Her vision was 20/20 in both eyes, and her intraocular pressure was 17/15 mmHg.
Four days later, right facial palsy was observed. Because of the local and systemic complications, the third cycle of NAIC was cancelled. Total exenteration was performed, and RT (6000 cGy) was performed 3 months later. Right facial palsy remained after the total exenteration. At the 69-month follow-up, the patient was disease-free.
A 54-year-old woman presented with a 1-month history of right eye vision loss with progressive proptosis. Her visual acuity at the first visit was 20/400 in the right eye and 20/20 in the left eye. Her intraocular pressure was 19/19 mmHg. Right proptosis of 6 mm was noted.
A CT scan showed a solid tissue mass with an irregular margin in the right orbit, with direct invasion into the adjacent bony orbit. The tubular pattern typical of ACC was confirmed on incisional biopsy.
Although viral infection during the immunosuppression phase of chemotherapy is not inherent to the intra-arterial route of delivery , we reduced the dose of cisplatin from 80 to 60 mg/m2 due to the systemic complication. The dose of doxorubicin was also reduced from 80 to 60 mg/m2 when the second and third NAIC cycles were performed. All three cycles of the NAIC regimen were completed in this patient, as originally planned.
Approximately 5 weeks later, total exenteration was performed. At the same time, bony erosion of the superior and lateral orbital rim was noted, and adjacent bone was removed using a rongeur. RT was initiated 6 weeks after surgery. No local recurrence or distal metastasis was observed over the next 59 months.
A 45-year-old woman presented with a 1-year history of eyelid swelling. The discomfort and lid oedema had aggravated over the last 3 months. At the time of presentation, visual acuity was 20/25 in both eyes, and the intraocular pressure was 16/16 mmHg.
Three days after NAIC, the patient complained of right facial pain, swelling, and discomfort on opening the mouth. Erythema was noted on the right cheek and neck. We infused dexamethasone (10 mg) intravenously, and an ice bag was applied. The erythema resolved. A follow-up CT obtained after 3 weeks showed that the size of the tumour had decreased from 3 to 2.3 cm (Figure 5b). However, the patient did not want to continue the NAIC; therefore, we could not complete the full NAIC regimen. After 1 month, total exenteration of the right orbit was performed. Removal of the lateral zygomatic bone was performed because of cancer invasion of the lateral orbital rim. In accordance with the therapeutic plan, postoperative irradiation (6000 cGy) was performed. We followed the patient for 48 months. At the last visit, the right inferior orbital rim showed increased intensity on the magnetic resonance imaging scan, and the patient is currently being followed up closely.
A 75-year-old man presented with a 3-month history of right eye pain and proptosis. He was diagnosed with ACC, and total exenteration was recommended at another hospital. He did not consent to this radical treatment. At the first visit to our hospital, his visual acuity was 20/25 in the right eye and 20/20 in the left eye. His intraocular pressure was 21/18 mmHg, and a 5-mm right eye proptosis was noted.
All three cycles of the NAIC regimen were completed, and definite size reduction was observed after the treatment (Figure 6b). Specific local complications related to NAIC were not encountered, and mild decreases in white blood cell and platelet counts were observed after the second NAIC cycle.
After completion of the NAIC regimen, the patient underwent mass removal with adjacent bone resection (Figure 6c). External RT (6300 cGy) was performed 1 month after surgery. His visual acuity during the follow-up period was 20/30 in the right eye and 20/20 in the left eye. Proptosis was not observed on performing exophthalmometry.
After 54 months from treatment, there was local recurrence of the tumour for which exenteration was recommended.
Tse et al.  recently reported that the cumulative 5-year ACC-specific death rate was 57.1% in a conventional treatment group, but only 16.7% in an intra-arterial chemotherapy treatment group. The cumulative 5-year recurrence rate was 71.4% in the conventional group and 23.8% in the chemotherapy group, emphasising the usefulness of intra-arterial chemotherapy in local disease control and in improving overall disease-free survival. Because ACC is extremely rare and has a poor prognosis, these results raise the possibility of using intra-arterial chemotherapy in the treatment of this disease. However, to date, few reports detailing the use of intra-arterial chemotherapy for ACC have been published [3, 4]. The effectiveness of most therapies for ACC is judged on the basis of retrospective case reports or on expert opinion because of the rarity of the condition; therefore, complications related to introducing new therapeutic modalities are worth noting. We have thus reported the complications that we experienced during intra-arterial chemotherapy and have further discussed interventional methods resulting in local complications.
With respect to selecting an artery for chemotherapy, Meldrum et al.  and Tse et al.  recommended using the ECA to inject a chemotherapeutic agent for treatment of lacrimal gland tumours. The authors explained that the ECA was the preferred artery because of concerns that the chemotherapeutic agents could be delivered into the cerebral circulation when injecting into arterial feeders originating from the ICA . However, in our experience, the feeding vessel to the tumour may not be always obvious on the ECA angiogram. Patient 1 had main lacrimal feeders from the ophthalmic artery of the internal carotid system instead of the ECA. Because of this anatomical disposition and because exenteration of the eye had already been planned, and further because contrast injections through the microcatheter did not show reflux into the cerebral circulation, we opted to infuse through the ICA feeder. Understanding the anatomical variations of the blood vessels that supply the lacrimal gland is required prior to performing intra-arterial selection. The lacrimal artery can branch out from the ophthalmic artery originating from the ICA, but it can also branch out from the MMA originating from the ECA. Moreover, it can receive a blood supply from both [6–8]. The orbit can receive a collateral supply from the distal maxillary artery and the infraorbital, sphenopalatine, and anterior deep temporal arteries. Because the ophthalmic artery was selected in patient 1, necrosis occurred in the eyeball as well as in the eyelid that received the blood supply from this branch. The toxicity of the antitumour agent is suggested as the cause of the eyelid and eyeball necrosis in this case. Although in this case there were no complications related to the chemotherapeutic agent being delivered into the cerebral circulation, the risk of injection into the cerebral circulation when selecting the ICA should be kept in mind.
In the present study, all patients survived until the last follow-up. These outcomes are in accordance with the successful results pertaining to local disease control and overall disease-free survival that have been reported previously . Imaging technology and supplementary treatments, including intra-arterial chemotherapy, are expected to play a positive role not only in enhancing survival rates, but also in preventing orbital exenteration. Several recent reports have stated that good survival is achieved by removing only the tumour and using plaque radiotherapy, without performing exenteration [10, 11]. These authors reported that conservative treatment was possible because radiation could be used for residual cancer cells and that this treatment would be especially useful for small children and monocular patients. However, in the present study, the patient who underwent only tumour resection and not exenteration (patient 4) showed tumour recurrence at the last follow-up. The tumour cells can exit the orbit along either the lacrimal nerve or the blood vessel from the time of diagnosis because of the micrometastasis and perineural invasion characteristics of ACC. To conclude that intra-arterial chemotherapy might prevent this type of local and possibly metastatic aggressiveness, further study is needed.
In conclusion, NAIC may increase the survival rate of patients with ACC and may represent a new treatment option for preservation of the eye in such cases. However, to decrease treatment-related complications and ensure completion of the three-cycle protocol, close observation through proper follow-up after treatment and appropriate management of adverse effects are necessary.
This study was supported by Soonchunhyang and Yonsei University research fund.
- Shields JA, Shields CL, Epstein JA, Scartozzi R, Eagle RC Jr: Review: primary epithelial malignancies of the lacrimal gland: the 2003 Ramon L. Font lecture. Ophthal Plast Reconstr Surg 2004, 20: 10–21. 10.1097/01.IOP.0000103003.87842.BBPubMedView ArticleGoogle Scholar
- Font RL, Smith SL, Bryan RG: Malignant epithelial tumors of the lacrimal gland: a clinicopathologic study of 21 cases. Arch Ophthalmol 1998, 116: 613–616. 10.1001/archopht.116.5.613PubMedView ArticleGoogle Scholar
- Meldrum ML, Tse DT, Benedetto P: Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol 1998, 116: 315–321. 10.1001/archopht.116.3.315PubMedView ArticleGoogle Scholar
- Tse DT, Benedetto P, Dubovy S, Schiffman JC, Feuer WJ: Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Am J Ophthalmol 2006, 141: 44–53. 10.1016/j.ajo.2005.08.068PubMedView ArticleGoogle Scholar
- Edge SB, Byrd DR, Compton CC, Fritz AG, American Joint Committee on Cancer: AJCC Cancer Staging Manual. 7th edition. New York, London: Springer; 2009.Google Scholar
- Ducasse A, Delattre JF, Flament JB, Hureau J: The arteries of the lacrimal gland. Anat Clin 1984, 6: 287–293. 10.1007/BF01654461PubMedView ArticleGoogle Scholar
- Erdogmus S, Govsa F: Importance of the anatomic features of the lacrimal artery for orbital approaches. J Craniofac Surg 2005, 16: 957–964. 10.1097/01.scs.0000179741.68294.1cPubMedView ArticleGoogle Scholar
- Hayreh SS: The ophthalmic artery: III. Branches. Br J Ophthalmol 1962, 46: 212–247. 10.1136/bjo.46.4.212PubMed CentralPubMedView ArticleGoogle Scholar
- Susser WS, Whitaker-Worth DL, Grant-Kels JM: Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999, 40: 367–398. 10.1016/S0190-9622(99)70488-3PubMedView ArticleGoogle Scholar
- Shields JA, Shields CL, Eagle RC Jr, Freire JE, Mercado GV, Schnall B: Adenoid cystic carcinoma of the lacrimal gland simulating a dermoid cyst in a 9-year-old boy. Arch Ophthalmol 1998, 116: 1673–1676. 10.1001/archopht.116.12.1673PubMedView ArticleGoogle Scholar
- Shields JA, Shields CL, Freire JE, Brady LW, Komarnicky L: Plaque radiotherapy for selected orbital malignancies: preliminary observations: the 2002 Montgomery Lecture, part 2. Ophthal Plast Reconstr Surg 2003, 19: 91–95. 10.1097/01.IOP.0000056020.66654.33PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.